AR040350A1 - Inhibidores de caspasa y usos de los mismos - Google Patents

Inhibidores de caspasa y usos de los mismos

Info

Publication number
AR040350A1
AR040350A1 ARP030102352A ARP030102352A AR040350A1 AR 040350 A1 AR040350 A1 AR 040350A1 AR P030102352 A ARP030102352 A AR P030102352A AR P030102352 A ARP030102352 A AR P030102352A AR 040350 A1 AR040350 A1 AR 040350A1
Authority
AR
Argentina
Prior art keywords
disease
halo
straight
ocf3
branched
Prior art date
Application number
ARP030102352A
Other languages
English (en)
Inventor
Michael Mortimore
Ronald Knegtel
John Studley
David Millan
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR040350A1 publication Critical patent/AR040350A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)

Abstract

Reivindicación 1: Un compuesto de fórmula (1), en donde: X es un CH o N; Y es halo, trifluorfenoxi o tetrafluorfenoxi; R2 es alquilo C1-6 de cadena recta o ramificada; R3 es hidrógeno, halo, OCF3, CN o CF3; y R4 es hidrógeno, halo, OCF3, SR, CN, CF3, Ar o T-Ar; en donde: T es O ó S; R es un alquilo C1-6 de cadena recta o ramificada; Ar es un anillo fenilo opcionalmente sustituido con 1 a 3 grupos seleccionados entre halo, CH3, CF3, CN, OMe, OCF3 y NR5R6; y R5 y R6 son, cada uno en forma independiente, H o alquilo C1-6 de cadena recta o ramificada, o R5 y R6, tomados juntos, forman un anillo de 5 a 7 miembros que opcionalmente contiene hasta 3 heteroátomos seleccionados entre O, S, NH y N(alquilo C1-6 de cadena recta o ramificada); siempre que Y sea halo, entonces R3 y R4 no son simultáneamente hidrógeno. Reivindicación 21: Una composición farmacéutica que comprende: a) un compuesto conforme a cualquiera de las reivindicaciones 1 a 20; b) un portador, adyuvante o vehículo farmacéuticamente aceptable. Reivindicación 22: Un método para tratar una enfermedad en un paciente, en donde dicha enfermedad se selecciona entre una enfermedad regulada por IL-1,una enfermedad regulada por apoptosis, una enfermedad inflamatoria, una enfermedad autoinmune, un trastorno óseo destructivo, un trastorno proliferativo, una enfermedad infecciosa, una enfermedad degenerativa, una enfermedad asociada con la muerte celular, una enfermedad por ingestión de exceso de alcohol dietario, una enfermedad regulada viral, trastornos de la retina, uveítis, peritonitis inflamatoria, osteoartritis, pancreatitis, asma, síndrome de insuficiencia respiratoria del adulto, glomerulonefritis, artritis reumatoidea, lupus eritematoso sistémico, esclerodermia, tiroiditis crónica, enfermedad de Grave, gastritis autoinmune, diabetes, anemia hemolítica autoinmune, neutropenia autoinmune, trombocitopenia, hepatitis activa crónica, miastenia grave, enfermedad intestinal inflamatoria, enfermedad de Crohn, psoriasis, dermatitis atópica, cicatrización patológica, enfermedad de injerto contra huésped, rechazo de transplante de órganos, apoptosis de órganos luego de danos por quemaduras, osteoporosis, leucemias y trastornos relacionados, síndrome mielodisplásico, trastorno óseo relacionado con mieloma múltiple, leucemia mielógena aguda, leucemia mielógena crónica, melanoma metastático, sarcoma de Kaposi, mieloma múltiple, choque hemorrágico, sepsis, choque séptico, quemaduras, siguelosis, mal de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington, enfermedad de Kennedy, enfermedad priónica, isquemia cerebral, epilepsia, isquemia de miocardio, enfermedad cardiaca aguda y crónica, infarto de miocardio, insuficiencia cardiaca congestiva, aterosclerosis, derivación aortocoronaria (bypass), atrofia muscular espinal, esclerosis lateral amiotrófica, esclerosis múltiple, encefalitis relacionada con HIV, envejecimiento, alopecia, dano neurológico debido a apoplejía, colitis ulcerativa, dano cerebral traumático, dano de la medula espinal, hepatitis B, hepatitis C, hepatitis G, fiebre amarilla, fiebre del dengue, o encefalitis japonesa, varias formas de enfermedad hepática, enfermedad renal, enfermedad del rinón poliquística, enfermedad ulcerosa duodenal y gástrica asociada con H. Pylori, infección de HIV, tuberculosis, meningitis, insuficiencia de órganos, tratamiento de complicaciones asociadas con derivaciones aortocoronarias (bypass), y una inmunoterapia para el tratamiento de varias formas de cáncer; en donde dicho método comprende la etapa de administrar a dicho paciente una composición farmacéutica conforme a la reivindicación 21. Reivindicación 31: Un método de preparación de un compuesto de fórmula (1), en donde dicho método comprende: hacer reaccionar un ácido o derivado ácido de fórmula (2), con un amino alcohol de fórmula (4), para proporcionar un compuestos de fórmula (3); convertir el intermediario (3) en compuesto (1), en donde: X es CH o N; Y es halo, trifluorfenoxi o tetrafluorfenoxi; R2 es alquilo C1-6 de cadena recta o ramificada; R3 es hidrógeno, halo, OCF3, CN o CF3; y R4 es hidrógeno, halo, OCF3, SR, CN, CF3, Ar o T-Ar; en donde: T es O ó S; R es un alquilo C1-6 de cadena recta o ramificada; Ar es un anillo fenilo opcionalmente sustituido con 1 a 3 grupos seleccionados entre halo, CH3, CF3,CN, OMe, OCF3 y NR5R6; R5 y R6 son, cada uno en forma independiente, H o alquilo C1-6 de cadena recta o ramificada, o R5 y R6, tomados juntos, forman un anillo de 5 a 7 miembros que opcionalmente contiene hasta 3 heteroátomos seleccionados entre O, S, NH y N(alquilo C1-6 de cadena recta o ramificada); y R7 es un grupo protector adecuado; siempre que cuando Y es halo, entonces R3 y R4 no son simultáneamente hidrógeno. Reivindicación 32: Un compuesto de fórmula (5), en donde: X es CH o N; R2 es alquilo C1-6 de cadena recta o ramificada; R3 es hidrógeno, halo, OCF3, CN o CF3; y R4 es hidrógeno, halo, OCF3, SR, CN, CF3, Ar o T-Ar; en donde: T es O ó S; R es un alquilo C1-6 de cadena recta o ramificada; Ar es un anillo fenilo opcionalmente sustituido con 1 a 3 grupos seleccionados entre halo, CH3, CF3, CN, OMe, OCF3 y NR5R6; y R5 y R6 son, cada uno en forma independiente, H o alquilo C1-6 de cadena recta o ramificada, o R5 y R6, tomados juntos, forman un anillo de 5 a 7 miembros que opcionalmente contiene hasta 3 heteroátomos seleccionados entre O, S, NH y N(alquilo C1-6 de cadena recta o ramificada).
ARP030102352A 2002-06-28 2003-06-27 Inhibidores de caspasa y usos de los mismos AR040350A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39259202P 2002-06-28 2002-06-28
US43507302P 2002-12-20 2002-12-20

Publications (1)

Publication Number Publication Date
AR040350A1 true AR040350A1 (es) 2005-03-30

Family

ID=30003264

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102352A AR040350A1 (es) 2002-06-28 2003-06-27 Inhibidores de caspasa y usos de los mismos

Country Status (19)

Country Link
US (2) US7553852B2 (es)
EP (1) EP1539701A1 (es)
JP (2) JP4616643B2 (es)
KR (1) KR20050013260A (es)
CN (1) CN100503572C (es)
AR (1) AR040350A1 (es)
AU (1) AU2003248758A1 (es)
BR (1) BR0312232A (es)
CA (1) CA2493646A1 (es)
IL (1) IL165986A0 (es)
MX (1) MXPA05000069A (es)
NO (1) NO20050851L (es)
NZ (1) NZ537807A (es)
PE (1) PE20040728A1 (es)
PL (1) PL374598A1 (es)
RU (1) RU2005102094A (es)
TW (1) TW200404783A (es)
UY (1) UY27872A1 (es)
WO (1) WO2004002961A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
CN100503572C (zh) 2002-06-28 2009-06-24 沃泰克斯药物股份有限公司 天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
SG150546A1 (en) 2004-03-12 2009-03-30 Vertex Pharma Processes and intermediates
NZ588448A (en) 2004-05-15 2012-01-12 Vertex Pharma Treating seizures using interleukin-1beta converting enzyme (ICE) inhibitors
CA2567080A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
JP5001150B2 (ja) * 2004-06-08 2012-08-15 ファミリーズ オブ スパイナル マスキュラー アトロフィー 脊髄性筋萎縮症のための２，４−ジアミノキナゾリン
CA2577060A1 (en) 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
CA2580642C (en) * 2004-09-17 2014-09-02 Biomas, Ltd. Novel tellurium compounds and their use as immunomodulators
CN101098855B (zh) * 2004-11-24 2012-06-06 沃泰克斯药物股份有限公司 3-[2-(3-酰氨基-2-氧代-2h-吡啶-1-基)-乙酰氨基]-4-氧代-戊酸衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途
CA2593005A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
US8987306B2 (en) * 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
US8258159B2 (en) * 2005-06-07 2012-09-04 The Trustees Of The University Of Pennsylvania Inhibitors of the α2β1/GPIa-IIa integrin
CN101268084A (zh) * 2005-07-28 2008-09-17 沃泰克斯药物股份有限公司 天冬氨酸特异性半胱氨酸蛋白酶抑制剂前体药物
WO2007027742A2 (en) * 2005-08-31 2007-03-08 The Trustees Of The University Of Pennsylvania SMALL MOLECULE INTEGRIN α2βl/GPIa-IIa ANTAGONISTS
NZ575198A (en) 2006-08-01 2012-05-25 Families Of Spinal Muscular Atrophy 2,4-diaminoquinazolines for spinal muscular atrophy
JP5271909B2 (ja) * 2006-09-11 2013-08-21 エム・エス・ディー・オス・ベー・フェー ２−（１−オキソ−１ｈ−イソキノリン−２−イル）アセトアミド誘導体
US20080160081A1 (en) * 2006-12-11 2008-07-03 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making, and methods of use
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
FR2923160B1 (fr) * 2007-11-02 2013-07-26 Pasteur Institut Composes destines a prevenir ou traiter une infection virale.
EP2635907A4 (en) 2010-11-05 2014-04-16 Univ Brandeis ALPHA-SYNUCLEINE CLIVED ICE AS A BIOLOGICAL MARKER
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
WO2013112788A1 (en) 2012-01-26 2013-08-01 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
KR20170015312A (ko) 2014-05-12 2017-02-08 코나터스 파마슈티칼스, 인크. 카스파제 억제제를 사용한 만성 간질환의 합병증의 치료
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
WO2017117478A1 (en) 2015-12-31 2017-07-06 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
US20190231770A1 (en) 2016-10-05 2019-08-01 Novartis Ag Combination compositions comprising fxr agonists for treating or preventing a fibrotic, cirrhotic disease or disorder
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
DD232699A1 (de) * 1983-11-18 1986-02-05 Adw Ddr Verfahren zur herstellung von chinazolin-4-on-3-alkansaeuren und deren estern
FR2582514B1 (fr) * 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) * 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
US6316415B1 (en) 1996-10-11 2001-11-13 Basf Aktiengesellschaft Sulfonamide interleukin-1β converting enzyme inhibitors
US6063794A (en) * 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
KR20000049048A (ko) 1996-10-11 2000-07-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인터루킨-1β 전환 효소의 아스파르테이트 에스테르 억제제
WO1998018781A2 (en) 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
RO122246B1 (ro) 1999-05-07 2009-03-30 Texas Biotechnology Corporation Derivaţi de acid propionic ce inhibă legarea integrinelor de receptorii acestora, compoziţie farmaceutică ce îi conţine şi utilizare
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
WO2000068188A1 (en) 1999-05-07 2000-11-16 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AR026748A1 (es) * 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
EP1289993B9 (en) 2000-06-07 2008-08-20 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
AU2002348533A1 (en) * 2001-10-09 2003-05-26 Vertex Pharmaceuticals Incorporated Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
AU2003211052A1 (en) 2002-02-11 2003-09-04 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
WO2003088917A2 (en) 2002-04-19 2003-10-30 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
CN100503572C (zh) 2002-06-28 2009-06-24 沃泰克斯药物股份有限公司 天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
CN101098855B (zh) 2004-11-24 2012-06-06 沃泰克斯药物股份有限公司 3-[2-(3-酰氨基-2-氧代-2h-吡啶-1-基)-乙酰氨基]-4-氧代-戊酸衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途

Also Published As

Publication number Publication date
CN1675184A (zh) 2005-09-28
MXPA05000069A (es) 2005-04-11
PE20040728A1 (es) 2004-10-23
JP4616643B2 (ja) 2011-01-19
UY27872A1 (es) 2003-12-31
WO2004002961A1 (en) 2004-01-08
CN100503572C (zh) 2009-06-24
RU2005102094A (ru) 2006-02-27
US20040072850A1 (en) 2004-04-15
AU2003248758A1 (en) 2004-01-19
CA2493646A1 (en) 2004-01-08
PL374598A1 (en) 2005-10-31
EP1539701A1 (en) 2005-06-15
IL165986A0 (en) 2006-01-15
US20090281128A1 (en) 2009-11-12
US7553852B2 (en) 2009-06-30
KR20050013260A (ko) 2005-02-03
BR0312232A (pt) 2005-05-10
NO20050851L (no) 2005-03-29
TW200404783A (en) 2004-04-01
US8129381B2 (en) 2012-03-06
JP2005533825A (ja) 2005-11-10
JP2010143942A (ja) 2010-07-01
NZ537807A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
AR040350A1 (es) Inhibidores de caspasa y usos de los mismos
JP2005533825A5 (es)
JP2003535865A5 (es)
CA2583022A1 (en) Acetamide compounds as fungicides
JP2018511647A5 (es)
WO2003080580A3 (en) Quinoline derivatives and their use as 5-ht6 ligands
JP2007525503A5 (es)
AR067896A1 (es) Procedimiento para sintetizar compuestos utiles para tratar hepatitis c
JP2003534325A5 (es)
RU2006134258A (ru) Ингибиторы каспаз и их применение
JP2006513220A5 (es)
IL278757A (en) Method for Preparation (3R, 4S) –3– Acetamido – 4 – Idyl– N– (Tert-Butyl) Pyrolidine – 3 – Carboxamide
RU2005140657A (ru) Ингибиторы каспаз и их применение
KR20010052325A (ko) 에포틸론 유도체, 이의 제조 방법 및 이의 용도
UA86013C2 (ru) Производные арилалкилкарбаматов, их получение и применение в лечении
WO2005061476A3 (en) Aroylfuranes and aroylthiophenes
ATE482199T1 (de) Menthancarbonsäureamidderivate mit kühlenden eigenschaften
WO2009044803A1 (ja) 不斉触媒マイケル反応生成物の製造方法
MXPA04002653A (es) Metodo para preparar compuestos de pirimidinona y sales farmaceuticamente aceptables del mismo.
CA2576647A1 (en) Vla-4 antagonists
TW200619201A (en) Process for the preparation of pyrazoles
TW200510366A (en) 1, 2, 4-trioxepanes as precursors for lactones
TW200510444A (en) Avermectins substituted in the 4" and 4'-positions having pesticidal properties
RU2013128602A (ru) Производные дифениламина: применение, способ синтеза и фрамацевтические композиции
EA201170899A1 (ru) Производные 2-пиридин-2-ил-пиразол-3(2h)-она, их получение и применение в терапии в качестве активаторов hif

Legal Events

Date Code Title Description
FB Suspension of granting procedure